Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer.

Date publication

novembre 2010

Journal

Clinical cancer research : an official journal of the American Association for Cancer Research

Auteurs

Membres identifiés du Cancéropôle Est :
Pr COUTANT Charles

Tous les auteurs :
Tabchy A, Valero V, Vidaurre T, Lluch A, Gomez H, Martin M, Qi Y, Barajas-Figueroa LJ, Souchon E, Coutant C, Doimi FD, Ibrahim NK, Gong Y, Hortobagyi GN, Hess KR, Symmans WF, Pusztai L

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/20829329

Résumé

We examined in a prospective, randomized, international clinical trial the performance of a previously defined 30-gene predictor (DLDA-30) of pathologic complete response (pCR) to preoperative weekly paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide (T/FAC) chemotherapy, and assessed if DLDA-30 also predicts increased sensitivity to FAC-only chemotherapy. We compared the pCR rates after T/FAC versus FACx6 preoperative chemotherapy. We also did an exploratory analysis to identify novel candidate genes that differentially predict response in the two treatment arms.

Mots clés

Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, therapeutic use, Biomarkers, Pharmacological, analysis, Biomarkers, Tumor, analysis, Breast Neoplasms, diagnosis, Carcinoma, Ductal, Breast, diagnosis, Cyclophosphamide, administration & dosage, Doxorubicin, administration & dosage, Female, Fluorouracil, administration & dosage, Gene Expression Regulation, Neoplastic, drug effects, Humans, Middle Aged, Paclitaxel, administration & dosage, Predictive Value of Tests, Prognosis, Treatment Outcome

Référence

Clin. Cancer Res.. 2010 Nov;16(21):5351-61